5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Elite Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Mar. 2026 was 46.85%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Elite Pharmaceuticals's 5-Year ROIIC % or its related term are showing as below:
ELTP's 5-Year ROIIC % is ranked better than 86.96% of 897
companies
in the Drug Manufacturers industry
Industry Median: 2.41
vs ELTP: 46.85
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Elite Pharmaceuticals 5-Year ROIIC % Related Terms
Elite Pharmaceuticals 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELTP vs EBS, NIKA, EOLS: 5-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals 5-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's 5-Year ROIIC % falls into.
Elite Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( 39.458408 (Mar. 2026) - 2.105 (Mar. 2021) )
/
( 97.53 (Mar. 2026) - 17.796 (Mar. 2021) )
=
37.353408
/
79.734
=
46.85%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Elite Pharmaceuticals (ELTP) has a 5-Year ROIIC % of 46.85 as of Mar. 2026. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Elite Pharmaceuticals and its competitors. According to the industry distribution chart, Elite Pharmaceuticals ranks #117 out of 897 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is Elite Pharmaceuticals' 5-Year ROIIC % too high?
Elite Pharmaceuticals' current 5-Year ROIIC % is 46.85. The Drug Manufacturers industry median 5-Year ROIIC % is 2.41. Elite Pharmaceuticals' value of 46.85 is 1844% above this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #117 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' 5-Year ROIIC % compare to EBS and NIKA?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #117 out of 897 companies for 5-Year ROIIC %. This places Elite Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median 5-Year ROIIC % is 2.41. Elite Pharmaceuticals' value of 46.85 is 1844% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Drug Manufacturers company?
The median 5-Year ROIIC % among Drug Manufacturers companies is 2.41, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current 5-Year ROIIC % of 46.85 is 1844% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year ROIIC % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current 5-Year ROIIC % is 46.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.56, compared to a current price of $0.34 — trading 39.1% below its estimated fair value. The current 5-Year ROIIC % is 46.85 and 1844% above the Drug Manufacturers industry median of 2.41. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current 5-Year ROIIC % is 46.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.34 is trading 39.1% below its estimated GF Value™ of $0.56.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
5-Year ROIIC %: 46.85
GF Value™: $0.56 vs. price of $0.34 (39.1% below fair value)
Industry Position: 1844% above the Drug Manufacturers median (#117 of 897)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
